Document 6527233

P. 01,‘03
Pharmaceutical,
Faulding
Inc.
11 Conii~rce Drive
Cranford. MO! 6New Jersey 07202
Fax Cover Sheet
DATE:
TIME: 1:18 PM
January 14,200O
Grea Oawis, Docket Management Branch
0epartmsnt of Health and Human Services
TO:
PHONE: 30: 627-8752
FAX: 301 594-l 174
Rockville, MD
PHONE:908 931-3805
908 7044150
Heike Maaser, PhD
Faudling Pharmaceuticals Co.
FROM:
FAX:
11 Commerce Drive, Cranford, NJ USA
Amendment to Citizen Suita@#ty Petition Docket
No, QQP- 2252lCPl
FE:
Number
o;l psges including
cover sheet: [ 3 ]
l&hssagc
Dear Mr. Devis,
Attached please find a copy of the Amendment to our Suitability Petition Docket No.
99P-225UCP1, submitted to the Dockets Management Branch on January 12,200.
On the advise of Gordon Johnston, our Consultant, I am forwarding this amendment via
fax to you to assure that our long oustanding approval will be discussed at the February
Yh meeting.
Faulding appreciares your consideration,
Regards,
Heike Maaser, Director, Regulatory Affairs
,
es
3" w
Jf+4--14-Z@~~
P.02103
13:03
Faulding Pharmaceutical CU.
A subsidiary
I -. ._._" ,,
A WoddofHeafth
AMENDMENT
January
TO CITIZEN
12,200O
‘Tdephgne
Facsimile
PETlTtON
4284
-
of fadding
(908)iOkOO
(908)709 4150
‘00 FEE?-1 P2:23
-
Dockets Management Branch
Department of Health and Human Services
Room 1-23
12420 Parklawn Drive
Rockville, MD 20857
Re:
M.
11 Commerce Drive
Cranfotd,New Jersey 07016
Amendment to Docket No. 99P-2252KPl
Suitability Petition - Pamidronate Disodiium Injection
3 mgimh,, 6.mg/mt, 9 rndrnt.
Dear Madam/Sir:
Faulding Pharmaceutical Company has been advised that .it must address the .‘\., y :.
Final Rule: Regulations Requiring Manufacturers te .Asses~,“~~~~.“~afety~~~
and
Effectiveness cf New Drugs and Biological Products in Pediatric Patients before
.
final action will be taken on the above referenced suitability petition. While in
’
disagreement with FDA’s new policy involving pediatric labeling as applied to the
approvability of Suitability Petitions for abbreviated new drug applications,
Faulding Pharmaceutical
is nevertheless submitting information in support of a
waiver for pediatric studies to their Suitability Petition Docket, No; 99P-2262/CPl.
- ‘. ”
In accord with 21 CFR 31455(c) FDA may grant fufl or partial waiver of the study
requirements on its own initiative or at the request of the applicant. Fauldiny
Pharmaceutical Company hereby requests a waiver for the following reasons:
I. The product, Pamidronate Disodium Injection (3mg/mL, 6 mg/mL, and
9 mg/mL) does not trulv reflect a chanqe in dosage form at point of
administration of the drug product to the patient and”wil!, therefore, not
change/increase
in any meaningful way the use of this product in the pediatric
patient population. The change from a lyophifized powder to a solution
provides a convenience to the pharmacist/hospital
only.
2. Faulding also evaluated the prevalence of the two disease states, Paget’s
disease and hypercalcemia in malignancy, in the pediatric population
(children from birth to 16 years of age) by conducting an exhaustive search of
the available literature in the United States, Based on this research, it does
not appear that the prevalence of either disease state meets the general
guide for a “substantial number” of pediatric patients which the Final Rule
defines as 50,000 pediatric patients.
3. The results of this search indicated that the pediatric prevalence of either
Paget’s disease of bone or hypercalcemia of malignancy, despite substantial
variation in epidemiological data, is sufficientJy low that identifying adequate
patients to enroll in a clinical study would present a significant challenge. To
identify patients and implement a proper study could potentially take several
years due to the apparent low incidence of these disease states. Therefore,
evaluation of the literature indicates that necessary studies are impossible or
highly impractical b8CauSe the number of patients is small and would also be
g8Ogfaphicaliy dispersed.
We believe that information provided in this amendment satisfies all apparent
outstanding issues related to this petition. We are confident that approval of our
petition v~ill now move forward speedily especially since the agency itself
communicated to Fauiding Pharmaceuticaf Co, already on December 6, 1999 that
pediatric studies would not be required.
Sincerely,
Faulding Pharmaceutical
Co.
Heike Maaser, Ph.D.
Director, Regulatory Affairs
TUTFlL
P.03